{
    "nctId": "NCT03792529",
    "briefTitle": "Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China",
    "officialTitle": "Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "Change from baseline targeted mutation analysis of ctDNA",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* patients with first treated or recurrent metastatic breast cancer, according to RECIST version 1.1 standard, confirmed by CT or MRI, have at least one measurable lesion.\n* HER2 positive or triple negative patients; (IHC++, fish amplification)\n* Patients with anti-HER2 treatment as first-line or not, and patients with HER2 positive can be treated with adjuvant therapy containing trastuzumab.\n\nExclusion Criteria:\n\n-",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}